Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 511 of 5804
-
New hope for Crohn's: four targeted drugs enter Mid-Stage trial
Disease control Recruiting nowCrohn's disease (CD) is a long-lasting disease that causes severe inflammation (redness, swelling), in the digestive tract, most frequently affecting the bowels. It can cause many different symptoms including belly pain, diarrhea, tiredness, and weight loss. Treatments are availa…
Phase: PHASE2 • Sponsor: AbbVie • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
Major trial aims to stop kidney failure in its tracks
Disease control Recruiting nowCAPTIVATE is an international, multi-centre, Phase III, adaptive, platform, randomised controlled trial in people with chronic kidney disease (CKD). CAPTIVATE aims to find the best treatment, or combination of treatments, that slow the progression of CKD so that fewer people dev…
Phase: PHASE3 • Sponsor: The George Institute • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
New shot could cut IV feeding for short bowel patients
Disease control Recruiting nowThe main aim of this clinical trial is to assess the efficacy and safety of PJ009 in patients aged ≥14 with short bowel syndrome (SBS) requiring parenteral nutrition. The main questions it aims to answer are: * How effective is PJ009 in treating short bowel syndrome? * Is PJ009 …
Phase: PHASE3 • Sponsor: Chongqing Peg-Bio Biopharm Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
New hope for advanced cancer: experimental drug DB-1419 enters human trials
Disease control Recruiting nowA Phase 1/2a First-in-Human Study of DB-1419 in Advanced/Metastatic Solid Tumors
Phase: PHASE1, PHASE2 • Sponsor: DualityBio Inc. • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
New drug combo aims to boost radiation success in EBV-related throat cancer
Disease control Recruiting nowThe purpose of the research is to test the safety and efficacy of the investigational drug in human subjects with cancer.
Phase: PHASE2 • Sponsor: Stanford University • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
Immunotherapy plus chemo shows promise for esophageal cancer before surgery
Disease control Recruiting nowThis is a domestic exploratory, single-arm clinical study enrolling patients with histologically or cytologically confirmed locally advanced esophageal squamous cell carcinoma (ESCC), aiming to evaluate the efficacy and safety of neoadjuvant adebrelimab plus chemotherapy for loca…
Phase: PHASE2 • Sponsor: The Affiliated Hospital of Putian University • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
No-Needle chemo patch takes aim at skin cancer
Disease control CompletedThis Phase 2 study evaluates the safety and efficacy of microneedle array (MNA) alone and in combination with two dose levels of doxorubicin (100µg and 200µg) in patients with nodular basal cell carcinoma. Efficacy is assessed using both clinical (visual) and histological endpoin…
Phase: PHASE2 • Sponsor: SkinJect, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New clip device aims to repair leaky heart valve without Open-Heart surgery
Disease control Recruiting nowThe primary objective of this trial is to demonstrate the safety and effectiveness of the DragonFly-T system in improving clinical outcomes in symptomatic patients with severe tricuspid regurgitation (TR), who are at intermediate or greater estimated risk for mortality or morbidi…
Phase: NA • Sponsor: Hangzhou Valgen Medtech Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 13:08 UTC
-
New biologic ZG006 targets tough lung and neuroendocrine cancers
Disease control Recruiting nowThis is a multicenter, open-label Phase I/II study consisting of two parts: Part 1 is a Phase I dose-escalation study of ZG006, aimed at evaluating the safety and tolerability of ZG006 in Participants with advanced small-cell lung cancer or neuroendocrine carcinoma. Upon complet…
Phase: PHASE1, PHASE2 • Sponsor: Suzhou Zelgen Biopharmaceuticals Co.,Ltd • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
New combo aims to put CLL into deep remission and let patients stop treatment
Disease control Recruiting nowThe goal of this phase II randomized open label study is to compare the rate of complete remission (CR) with undetectable minimal residual disease (uMRD) obtained with zanubrutinib in combination with obinutuzumab with two different schedules of administration of obinutuzumab (st…
Phase: PHASE2 • Sponsor: PETHEMA Foundation • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
Gene therapy trial aims to tame Parkinson's symptoms
Disease control OngoingA phase Ⅰ/Ⅱ study to evaluate the tolerability, safety, and efficacy of VGN-R09b in pa-tients with Parkinson's disease
Phase: PHASE1, PHASE2 • Sponsor: Shanghai Vitalgen BioPharma Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
Black dads step up: new study enlists fathers to shield girls from HIV
Prevention Recruiting nowThe scientific premise of this research is that individual, interpersonal, and structural factors impact Black girls' sexual reproductive health outcomes (sexually transmitted infection (STI) and Human Immunodeficiency Virus (HIV)) and experience of sexual violence. This study ex…
Phase: NA • Sponsor: University of Illinois at Chicago • Aim: Prevention
Last updated Jun 27, 2026 12:08 UTC
-
New combo therapy shows promise for untreatable liver cancer
Disease control OngoingThe goal of this clinical trial is to evaluate whether sequential transarterial chemoembolization (TACE) followed by stereotactic body radiotherapy (SBRT) combined with targeted immunotherapy is effective and safe for patients with intermediate to advanced hepatocellular carcinom…
Sponsor: Nanfang Hospital, Southern Medical University • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
Freezing or burning heart nerves: which works best for slow heartbeat?
Disease control Recruiting nowBradyarrhythmias are conditions where the heart beats too slowly, causing symptoms like dizziness, fainting, and fatigue. In some patients, these slow heart rhythms are caused by overactivity of the vagus nerve (the part of the nervous system that slows the heart down). Cardione…
Phase: NA • Sponsor: Tomsk National Research Medical Center of the Russian Academy of Sciences • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
CAR t therapy takes on lupus, MS, and more in first human safety trial
Disease control Recruiting nowA Phase 1 study of HBI0101 BCMA-CART in B-Cell Mediated Autoimmune Rheumatic Diseases. The goal of the study is evaluation of safety and identification of the maximum HBI0101 CART dose that may be administered safely to patients with B-cell mediated autoimmune disease.
Phase: PHASE1 • Sponsor: Polina Stepensky • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Cholesterol drug may block melanoma spread in High-Risk patients
Prevention OngoingThis clinical trial tests whether atorvastatin prevents metastasis of resected high-risk stage IIA, IIB or IIIA melanoma. The vast majority of melanomas are diagnosed at an early, localized stage. However, approximately 10-15% of these localized melanomas will eventually metastas…
Phase: PHASE2 • Sponsor: OHSU Knight Cancer Institute • Aim: Prevention
Last updated Jun 27, 2026 11:00 UTC
-
New vaccine aims to keep leukemia in remission
Disease control Recruiting nowAcute myeloid leukemia (AML) is the most common acute leukemia in adults. While approximately 70% of patients achieve complete remission (CR) with induction chemotherapy, traditional consolidation therapy (predominantly high-dose cytarabine) has a persistently high recurrence rat…
Phase: PHASE1 • Sponsor: Fujian Medical University Union Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
Which blood thinner combo best prevents a second stroke?
Disease control Recruiting nowAlong with the current clinical trial, the efficacy and safety of a 180 mg loading dose of ticagrelor administered within 24 hours of the first-ever large-vessel minor stroke or TIA compared to 300 mg clopidogrel were assessed through NIHSS, mRS, and possible adverse effects.
Phase: PHASE3 • Sponsor: Kafrelsheikh University • Aim: Disease control
Last updated Jun 26, 2026 13:49 UTC
-
AI could help surgeons spot aggressive kidney tumors before operating
Diagnosis Recruiting nowThis study aims to develop and validate a contrast-enhanced CT-based deep-learning model for automatic and accurate preoperative discrimination between T1-T2 and T3 renal cell carcinoma. By quantifying the model's diagnostic performance on an independent test set-using AUC, sensi…
Sponsor: Peking University First Hospital • Aim: Diagnosis
Last updated Jun 26, 2026 15:34 UTC
-
New procedure aims to keep weight off after GLP-1 drugs are stopped
Disease control OngoingFractyl is evaluating Revita Duodenal Mucosal Resurfacing (DMR) in the REMAIN-1 pivotal study, which is designed to include two cohorts - an open label cohort referred to as REVEAL-1, and a randomized cohort, which includes both a midpoint analysis and a pivotal analysis. Patient…
Phase: NA • Sponsor: Fractyl Health Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC